Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sigrid Therapeutics Announces Collaboration with Cencora to accelerate commercialization of revolutionary SiPore® technology for obesity and diabetes prevention

Stockholm, Sweden – Thursday January 25, 2024. Sigrid Therapeutics, a clinical-stage healthtech company dedicated to revolutionizing the management of obesity and diabetes prevention with a novel, fast-acting, non-pharmaceutical technology, announced today it entered into an agreement with Cencora  (formerly AmerisourceBergen) aimed at accelerating the commercialization of its SiPore® technology.SiPore21®, the company's flagship product, is currently undergoing SHINE clinical trials as an innovative medical device designed for sustained blood sugar and weight

Terrafame has strengthened its financing position

Terrafame’s financing arrangements consist of a repayment of EUR 142 million in shareholder loans to Galena and Mandatum through stock option exercises and entering into a EUR 250 million loan agreement from a Nordic bank club. As part of strengthening Terrafame Ltd’s (“Terrafame”) financing position, funds under the management of Galena Asset Management (“Galena”) and Mandatum Holding Ltd (“Mandatum”) have exercised stock options previously granted to them. The funds received from the stock options have been used to repay the EUR 142 million long-term term loans from Trafigura and

Invitation to presentation of Sedana Medical’s fourth quarter and year-end report for 2023

Sedana Medical AB (publ) plans to present its fourth quarter and year-end report for 2023 on Thursday February 15 at 13:30 CET.According to the financial calendar, Sedana Medical plans to publish the fourth quarter and year-end report for 2023 on Thursday February 15 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Johan Spetz, CFO, and Peter Sackey, CMO, as well as answer questions. Date: Thursday, February 15 2024 Time (CET): 13:30 More info and

Transaction in Own Shares

    25 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |24/01/2024|+-----------------------------------------------------------

Quarterly Factsheet

To:  PR Newswire From:  Strategic Equity Capital PLC LEI:   2138003R5GB8QZU2G577 Date:  25 January 2024     Quarterly Factsheet   The Company announces that its Factsheet and Commentary for the quarter ended 31 December 2023 is now available on the Company's website at:   Factsheet: https://greshamhouse.com/wp-content/uploads/2024/01/Gresham-House-SEC-plc-31-December-2023-factsheet.pdf   Commentary: https://greshamhouse.com/wp-content/uploads/2024/01/Strategic-Equity-Capital-plc-Factsheet-Commentary-Q4-2023.pdf   For further information,

Proact and Arctic Wolf partner to expand security services for the Nordic market

Proact, Europe's leading independent data centre specialist and cloud services provider, has partnered with global cybersecurity specialist Arctic Wolf to elevate cybersecurity services in the Nordic market.With evolving cyber threats that pose a significant risk to businesses, safeguarding data has become more crucial than ever. With over a decade of experience delivering security services from its Security Operation Centres (SOC), Proact is a trusted cybersecurity partner for enterprise businesses and the public sector in the European market. The collaboration with Arctic Wolf in the

BEXMAB Insights into Patient Profiles

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population   Company Announcement   TURKU, Finland / BOSTON, Massachusetts – January 25, 2024 – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided details from its further analysis of data from the

Interim report fourth quarter 2023

Fourth quarter 2023 A good ending to the year Continuing operations · Order intake SEK 30,062 million (30,751) · Order intake, at fixed exchange rates, declined by 2% · Revenues SEK 31,816 million (31,094) · Revenue growth, at fixed exchange rates 2% · Adjusted EBITA SEK 6,211 million (6,413) · Adjusted EBITA margin 19.5% (20.6) · Adjusted EBIT SEK 5,738 million (5,977) · Adjusted EBIT margin 18.0% (19.2) · Adjusted profit before tax SEK 5,107 million (5,587) · Profit for the period SEK 4,259 million (3,435) · Adjusted profit for the period SEK 4,047

Geert Follens, Daniel Nodhäll and Michael Rauterkus proposed as new Board members of AB Electrolux

The Nomination Committee of AB Electrolux proposes election of Geert Follens, Daniel Nodhäll and Michael Rauterkus as new members of the Board of Directors at the Annual General Meeting of AB Electrolux on March 27, 2024. The Nomination Committee further proposes re-election of Petra Hedengran, Ulla Litzén, Karin Overbeck, David Porter, and Jonas Samuelson, as Board members.As previously communicated, Torbjörn Lööf is proposed to be elected as the new Chairman of the Board of Directors since Staffan Bohman, the current Chairman of the Board of Directors, has announced that he will not be

Peab rebuilds wastewater treatment plant in Luleå

Peab has been commissioned to rebuild Uddebo wastewater treatment plant in Luleå. The customer is Luleå miljöresurs AB (Lumire) and the contract is worth SEK 157 million.The project is part of the work on the Eastern Link, where new main pipelines for wastewater are being laid to the plant. Peab will build and install a new intake section with an inlet pump station, preliminary treatment and grit chambers. “I’m proud that we with local resources have been entrusted by Lumire to carry out this project with focus on sustainability. The wastewater treatment plant is an important community

Fiskars Corporation to publish its Financial Statement Release 2023 on February 8, 2024

Fiskars CorporationPress ReleaseJanuary 25, 2024 at 9:00 a.m. EET Fiskars Corporation to publish its Financial Statement Release 2023 on February 8, 2024 Fiskars Corporation will publish its Financial Statement Release for 2023 on February 8, 2024 at approximately 8:30 a.m. (EET). The Financial Statement Release will be available on the Group's website www.fiskarsgroup.com after publication. WebcastA webcast on the fourth quarter and full year results will be held on February 8, 2024 at 14:00 p.m. (EET). It will be held in English and can be followed at https://fiskars.

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act Musti Group plc                         Stock Exchange Release                                         25 January 2024 at 9.00 a.m. Musti Group plc (the “Company”) has on 24 January 2024 received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act from JPMorgan Chase & Co, according to which JPMorgan Securities PLC’s (“JP Morgan”) direct holding of the shares and votes of the Company increased above the threshold of 5 percent on

Metsä Group selected Fortum Recycling & Waste as the main partner for the Kemi pulp mill demolition project

Metsä Group and Fortum Recycling & Waste have signed an agreement on dismantling the old pulp mill in Kemi, Finland. Fortum Recycling & Waste will be the main contractor for the demolition project and the demolition site will employ approximately 50 people. The price of the demolition contract will not be disclosed. Metsä Group's old pulp mill in Kemi ceased operations in autumn 2023 with the start-up of a new Kemi bioproduct mill. The safety procedures and demolition of the old mill was started immediately after the mill shutdown. The actual demolition will start in early 2024 and will

Sandvik implements restructuring program to continue strengthen operational efficiency

Sandvik is continuously looking at ways to strengthen operational efficiency and resilience and have now decided to implement a new program of restructuring measures, supporting the strategy and the financial targets of the Group. The new measures include consolidation of productions units and optimizing the structure of the organization. The measures are group-wide and global. The program will generate annual savings of about SEK 1.2 billion. The share of total annualized savings expected to be reached by end of 2024 and end of 2025 are approximately around 80% and 100%, respectively.

NextCell publishes its Interim Report 1 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.First quarter (2023-09-01 until 2023-11-30) ● Operating Income amounted to 4,695 (3,012) TSEK, of which   Cellaviva amounted to 4,218 (2,137) TSEK.● Operating result amounted to -9,

Veterinary hospital at Wihlborgs property in Helsingborg

In autumn 2024, AWAKE Djursjukhus (en: veterinary hospital) will open in the former post sorting centre (Posten 1) in Gåsebäck in southern Helsingborg. The high demand for qualified veterinary care is the reason for the expansion. The lease is for 2,000 square metres and extends for 15 years.AWAKE Djursjukhus has already been providing emergency and specialist care for cats and dogs in Södermalm in Stockholm. The company is now expanding operations with AWAKE Djursjukhus Helsingborg, which will provide emergency and specialist care for cats and dogs in the same way, 24-hours a day, 365 days

Invitation: Presentation of Ambea’s fourth quarter 2023 results

Hosts: Mark Jensen, CEO and Benno Eliasson, CFO.On 8[th] of February at 07:00 (CET) Ambea will publish its’ fourth quarter 2023 results. In connection to the announcement, Ambea will host a telephone conference at 10:00 (CET) on Thursday, 8[th] of February. The presentation will be held in English and available as webcast on www.ambea.com or direct link:https://edge.media-server.com/mmc/p/72p94oom Telephone conference To participate the conference call, register before the call using the link below. Upon registration you will receive a dial-in number and a unique personal PIN

Aker Carbon Capture ASA: Fourth quarter 2023 results

In the fourth quarter 2023, Aker Carbon Capture recorded high commercial activity across Europe and the United States. The company’s order backlog increased to NOK 2.6 billion, up from NOK 1.3 billion in the same period last year. Revenues rose to NOK 573 million, up 139% compared to the same period last year. The cash position at the end of the fourth quarter was solid at NOK 1.1 billion.“Aker Carbon Capture is experiencing an acceleration in market activity and strong interest in our growing range of modular carbon capture facilities. In 2023, we cemented our leading market position

Year-end report January–December 2023

Strong cash flow and efficiency gains ends a 2023 heavily impacted by market headwind  Key highlights · Weak volumes in North America and negative price and mix impact in both regions  · Sequentially lower input costs, mainly related to pulpwood in Europe  · Another strong delivery of our efficiency enhancement program · Excellent cash delivery through working capital focus · Negative profit impact from revaluation of biological assets in the associated company BSÖ · The Board of Directors proposes a dividend of SEK 2.00 per share (7.50) Quarterly data Q4 ·

Swedbank Economic Outlook: Near-term headwinds – but better by summer

Inflation will fall, interest rates will decline and household real income will rise in 2024 – paving the way for the Swedish economy to make a rapid recovery in 2025. The near-term outlook presents challenges, however, and the labour market will weaken this year. The Riksbank will start lowering the policy rate in May, and fiscal policy will become more expansive in 2025, according to Swedbank Economic Outlook.“After two years of declining income, households are beginning to see signs of hope as inflation falls and public transfers to households increase. However, consumption will remain

Panoro Energy – Trading Statement and Operations Update

Oslo, 25 January 2024 – Panoro Energy ASA (“Panoro” or the “Company”) provides an update in advance of its full year 2023 results which are scheduled for release on 22 February 2024. Information contained within this release is unaudited and may be subject to further review and amendment. 2023 was a record year for Panoro with revenues estimated at USD 217 million and group working interest production averaging approximately 8,500 bopd. With the mid-point of 2024 full-year production guidance representing a ~40 per cent increase on 2023 levels, driven by the drilling campaigns

Intrum AB – Year-end announcement 2023

· Seasonally strong end to a transitory year · Income flat vs. strong Q4 ‘22 and up 3 per cent vs. FY ’22 · Full year EBIT increased to SEK 4,364 M vs SEK 154 M (inclusive of JV write down) · EBIT includes SEK 541 M for the FY ’23 in respect of costs to execute the cost saving program · Adjusted Income was up 8 percent vs. Q4 ’22 and 5 percent vs. FY ’22 primarily driven by M&A activity in Servicing segment · Adjusted EBIT reduced by 1 percent vs. Q4 ’22 and 13 percent vs. FY ’22 driven by cost growth in excess of income · Leverage ratio flat at 4.4x (including 0.1x

Year-end Report 2023

JANUARY 1 – DECEMBER 31, 2023(compared with the corresponding period a year ago) · Net sales increased 12.1% to SEK 147,147m (131,320). Sales growth, including organic sales growth and acquisitions, amounted to 6.7%, of which volume accounted for -3.7%, price/mix for 9.5% and acquisitions for 0.9%. · Operating profit before amortization of acquisition-related intangible assets (EBITA) increased 68% to SEK 16,607m (9,876) · Adjusted EBITA increased 57% to SEK 18,898m (12,047) and the adjusted EBITA margin increased 3.6 percentage points to 12.8% (9.2) · Profit for the period

There are no items matching the current filter
There are no more items matching the current filter
Back to top